5 Big Drug Stocks That May Continue to Outperform in 2026
View original at finance.yahoo.com5 Big Drug Stocks That May Continue to Outperform in 2026 After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
J&J is on track to achieve a mid-30s percentage core operating margin by 2026
80% confidenceA substantial portion of growth through 2029 is expected to be driven by the robust performance of Skyrizi and Rinvoq
80% confidenceOrforglipron has the potential to be a more convenient alternative to injectable treatments like Zepbound and rival Novo Nordisk's Wegovy
80% confidenceJ&J expects better growth in the MedTech business in 2026 than 2025 levels, driven by increased adoption of newly launched products across all MedTech platforms and increased focus on higher-growth markets
80% confidenceJ&J expects accelerated growth in the Innovative Medicine segment to be driven by its key products as well as new drugs and recently launched products in 2026
80% confidenceRapid innovation, increased use of AI in drug development, positive pipeline/regulatory developments and continued M&A momentum signal a favorable growth outlook for 2026
80% confidenceAmgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars, to continue to drive top-line growth in 2026
80% confidenceAstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period
80% confidenceMounjaro and Zepbound are expected to continue to see strong demand in 2026
80% confidenceStrong immunology market growth, market share gains and momentum from new indications are expected to drive Skyrizi and Rinvoq growth
80% confidenceThe pending separation of its Orthopaedics franchise in the MedTech segment should improve its MedTech unit's growth and margins, as the Orthopaedics franchise has been a slow-growth business for J&J
80% confidenceSales of Prolia and Xgeva are expected to erode in the fourth quarter of 2025 and in 2026, as some biosimilars have been launched in the U.S. market
80% confidenceAstraZeneca believes that many of the new medicines will have the potential to generate more than $5 billion in peak-year revenues
80% confidenceAstraZeneca expects to generate $80 billion in total revenues by 2030
80% confidenceAstraZeneca plans to launch 20 new medicines by 2030, with nine new medicines already launched/approved
80% confidenceAbbVie expects a high single-digit CAGR through 2029, with no significant LOE events for the rest of this decade
80% confidenceInnovation is at its peak for the industry, with key spaces like obesity, cell and gene therapy, inflammation, rare disease, neuroscience and next-gen oncology treatments attracting investor attention
80% confidence
Data points we hold from this source
| AbbVie Inc. · eps estimate | 14.42 USD |